News & Research - HBM Partners AG

NEWS & RESEARCH

Portfolio News

HBM in the News

Industry Reports

Arrakis Therapeutics Raises $75M Series B To Develop Small‐Molecule Medicines Targeting RNA (112 KB)
18.4.2019
Download
HOOKIPA Pharma Announces Pricing of Initial Public Offering (131 KB)
17.4.2019
Download
SpringWorks Therapeutics Completes $125 Million Series B Financing (129 KB)
1.4.2019
Download
iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019 (121 KB)
29.3.2019
Download
HOOKIPA PROPOSES IPO AS ITS CANCER VACCINES HEAD TOWARDS THE CLINIC (17 KB)
22.3.2019
Download
Adrenomed’s Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II (178 KB)
21.3.2019
Download
Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Cutaneous Systemic Sclerosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor (363 KB)
4.3.2019
Download
Principia Biopharma Announces Positive Data from Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation (29 KB)
2.3.2019
Download
HOOKIPA Pharma Raises $37.4 million (€33.2 million) in Series D Financing (222 KB)
26.2.2019
Download
Forbius Announces a Clinical Trial Collaboration with the Myeloproliferative Neoplasm Research Consortium to Evaluate AVID200 a Novel TGF beta Inhibitor in Myelofibrosis (95 KB)
14.2.2019
Download

<3 4 567 8 >

Andreas Wicki, CEO HBM Healthcare Investments AG “The importance of biotech as the backbone of innovation of the pharma industry is growing all the time.” (156 KB)
18.08.2020
Download Read more
«Bedeutung von Biotech als Innovations-Rückgrat der Pharma-Industrie nimmt stetig zu» (196 KB)
18.08.2020
Download Read more
Biotech im Hoch: Nicht alle Healthcare-Unternehmen kommen gleich durch die Corona-Krise (499 KB)
25.07.2020
Download Read more
Virus eröffnet Anlage-Chancen (100 KB)
2.4.2020
Download Read more
Pharmaprofis kaufen keine Corona-Aktien (123 KB)
1.4.2020
Download Read more
Der Bedarf der Pharmakonzerne nach neuen Medikamenten ist ungestillt - Interview Dr. Andreas Wicki (302 KB)
6.11.2019
Download Read more
Investing in biotechnology - a lucrative approach (304 KB)
1.9.2019
Download Read more
Investieren in die Biotechnologie – ein aktiver Ansatz zahlt sich aus (4594 KB)
1.9.2019
Download Read more
Interview with Andreas Wicki (351 KB)
Download Read more
Interview with Ivo Staijen (263 KB)
17.7.2019
Download Read more
Biotech-Unternehmen schwimmen im Geld (309 KB)
25.5.2019
Download Read more
„Ungebremste Innovationskraft" (628 KB)
1.5.2019
Download Read more
Unbridled Capacity for Innovation (101 KB)
1.5.2019
Download Read more
Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)
23.1.2019
Download Read more
Investing in listed private equity – more than just an alternative (197 KB)
23.1.2019
Download Read more
Kleine Hersteller, grosses Potenzial (1007 KB)
1.1.2019
Download Read more
Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)
4.11.2018
Download Read more
A Biotechnology Bonanza (397 KB)
1.10.2018
Download Read more
Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)
13.8.18
Download Read more
Die Reize der Swiss Biotechs (581 KB)
25.7.2018
Download Read more

Trends in New Drug Approvals

Report covers new drugs approved by US FDA. The latest report as well as a list of new drug approvals since 2003 are available for download.

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)
Download
FDA Approved NMEs 2003-2018 (86 KB)
Download

HBM Pharma/Biotech M&A Report

HBM Partners carries out an ongoing analysis of all trade sales of public and private US and European biotech and pharma companies. The latest HBM Pharma/Biotech M&A Report as well as information on M&A transactions since 2005 are available for download:

Credits

Sitemap

Arrakis Therapeutics Raises $75M Series B To Develop Small‐Molecule Medicines Targeting RNA (112 KB)

HOOKIPA Pharma Announces Pricing of Initial Public Offering (131 KB)

SpringWorks Therapeutics Completes $125 Million Series B Financing (129 KB)

iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019 (121 KB)

HOOKIPA PROPOSES IPO AS ITS CANCER VACCINES HEAD TOWARDS THE CLINIC (17 KB)

Adrenomed’s Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II (178 KB)

Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Cutaneous Systemic Sclerosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor (363 KB)

Principia Biopharma Announces Positive Data from Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation (29 KB)

HOOKIPA Pharma Raises $37.4 million (€33.2 million) in Series D Financing (222 KB)

Forbius Announces a Clinical Trial Collaboration with the Myeloproliferative Neoplasm Research Consortium to Evaluate AVID200 a Novel TGF beta Inhibitor in Myelofibrosis (95 KB)

Andreas Wicki, CEO HBM Healthcare Investments AG “The importance of biotech as the backbone of innovation of the pharma industry is growing all the time.” (156 KB)

«Bedeutung von Biotech als Innovations-Rückgrat der Pharma-Industrie nimmt stetig zu» (196 KB)

Biotech im Hoch: Nicht alle Healthcare-Unternehmen kommen gleich durch die Corona-Krise (499 KB)

Virus eröffnet Anlage-Chancen (100 KB)

Pharmaprofis kaufen keine Corona-Aktien (123 KB)

Der Bedarf der Pharmakonzerne nach neuen Medikamenten ist ungestillt - Interview Dr. Andreas Wicki (302 KB)

Investing in biotechnology - a lucrative approach (304 KB)

Investieren in die Biotechnologie – ein aktiver Ansatz zahlt sich aus (4594 KB)

Interview with Andreas Wicki (351 KB)

Interview with Ivo Staijen (263 KB)

Biotech-Unternehmen schwimmen im Geld (309 KB)

„Ungebremste Innovationskraft" (628 KB)

Unbridled Capacity for Innovation (101 KB)

Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)

Investing in listed private equity – more than just an alternative (197 KB)

Kleine Hersteller, grosses Potenzial (1007 KB)

Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)

A Biotechnology Bonanza (397 KB)

Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)

Die Reize der Swiss Biotechs (581 KB)

Trends in New Drug Approvals

Analysis of FDA Approvals 2018 and Previous Years (1147 KB)

FDA Approved NMEs 2003-2018 (86 KB)

HBM Pharma/Biotech M&A Report

Biopharma M&A Update H1 2019 and Potential Implications of Mega Mergers for Smaller Biopharma Deal Making (470 KB)

HBM Pharma / Biotech M&A Report 2020 (1299 KB)

Pharma / Biotech M&A Transctions 2005-2019 (119 KB)